C'bon Cosmetics Co.,Ltd.
C'bon Cosmetics Co.,Ltd. (4926.T) Financial Performance & Income Statement Overview
Review C'bon Cosmetics Co.,Ltd. (4926.T) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
C'bon Cosmetics Co.,Ltd. (4926.T) Income Statement & Financial Overview
Access detailed annual and quarterly income data for C'bon Cosmetics Co.,Ltd. 4926.T financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.30B | $2.23B | $2.30B | $2.02B |
| Cost of Revenue | $480.03M | $544.00M | $546.88M | $525.00M |
| Gross Profit | $1.82B | $1.68B | $1.75B | $1.49B |
| Gross Profit Ratio | $0.79 | $0.76 | $0.76 | $0.74 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.69B | $1.63B | $1.68B | $1.58B |
| Operating Expenses | $1.69B | $1.63B | $1.68B | $1.57B |
| Total Costs & Expenses | $2.17B | $2.18B | $2.22B | $2.10B |
| Interest Income | $119000.00 | $0.00 | $0.00 | $385000.00 |
| Interest Expense | $0.00 | $0.00 | $4000.00 | $196000.00 |
| Depreciation & Amortization | $25.31M | $35.50M | -$9.50M | $35.50M |
| EBITDA | $132.04M | $85.50M | $63.81M | -$50.50M |
| EBITDA Ratio | $0.06 | $0.04 | $0.03 | -$0.03 |
| Operating Income | $132.97M | $49.00M | $73.31M | -$85.00M |
| Operating Income Ratio | $0.06 | $0.02 | $0.03 | -$0.04 |
| Other Income/Expenses (Net) | -$26.22M | $5.00M | -$9.51M | $1.00M |
| Income Before Tax | $106.75M | $54.00M | $63.80M | -$84.00M |
| Income Before Tax Ratio | $0.05 | $0.02 | $0.03 | -$0.04 |
| Income Tax Expense | -$55.47M | $18.00M | $20.42M | $20.00M |
| Net Income | $162.22M | $36.00M | $43.38M | -$104.00M |
| Net Income Ratio | $0.07 | $0.02 | $0.02 | -$0.05 |
| EPS | $37.59 | $8.41 | $10.13 | -$24.30 |
| Diluted EPS | $37.59 | $8.41 | $10.13 | -$24.30 |
| Weighted Avg Shares Outstanding | $4.28M | $4.28M | $4.28M | $4.28M |
| Weighted Avg Shares Outstanding (Diluted) | $4.28M | $4.28M | $4.28M | $4.28M |
Over the past four quarters, C'bon Cosmetics Co.,Ltd. demonstrated steady revenue growth, increasing from $2.02B in Q1 2024 to $2.30B in Q4 2024. Operating income reached $132.97M in Q4 2024, maintaining a consistent 6% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $132.04M, reflecting operational efficiency. Net income rose to $162.22M, with EPS at $37.59. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan